Comprehensive lung injury pathology induced by mTOR inhibitors.
Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibroproliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors.
Aparicio
Guadalupe
G
Oncology Research Lab, INIBIC, A Coruña, Spain.
Calvo
Moisés B
MB
Medina
Vanessa
V
Fernández
Ovidio
O
Jiménez
Paula
P
Lema
Martina
M
Figueroa
Angélica
A
Antón Aparicio
Luis M
LM
D006801:Humans; D008168:Lung / Q000473:pathology*; D055370:Lung Injury / Q000139:chemically induced*; D008954:Models, Biological; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000378:metabolism*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D017382:Reactive Oxygen Species / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases
D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases